Nanosomal Docetaxel Lipid Suspension-Based Chemotherapy in Breast Cancer: Results from a Multicenter Retrospective Study

Purpose: The purpose of this study was to evaluate the efficacy and safety of nanosomal docetaxel lipid suspension (NDLS, DoceAqualip)-based chemotherapy in breast cancer.

Methods: Medical charts of patients with breast cancer, who were treated and followed up with NDLS (75–100 mg/m²; 3-week cycle)-based chemotherapy from August 2014 to September 2018, were analyzed in this multicenter, retrospective study. The study endpoints were overall response rate (ORR: complete response [CR]+partial response [PR]) and disease control rate (DCR: CR+PR+stable disease [SD]) in neoadjuvant and metastatic settings. Overall survival (OS) and safety were evaluated for all settings.

Results: Of 91 patients (neoadjuvant: 12, adjuvant: 61, metastatic: 18), efficacy evaluation in 29 patients (neoadjuvant: 12/12, metastatic: 17/18) demonstrated an ORR and DCR of 100%, respectively, in the neoadjuvant setting, and an ORR of 64.7% and DCR of 70.6%, respectively, in the metastatic setting. At a median follow-up of 21.6 months (range: 2.1 to 49.9 months), median OS was not reached in neoadjuvant and adjuvant settings, and it was 30.4 months in metastatic settings. At least one adverse event (AE) was reported in 59.3% of patients. Anemia, thrombocytopenia, lymphopenia, and neutropenia were the most common hematological AEs reported while hyperglycemia and alteration in liver function tests were the most common non-hematological AEs. NDLS-based treatment was well tolerated without any new safety concerns.

Conclusion: Nanosomal docetaxel lipid suspension-based chemotherapy was efficacious and well tolerated in the treatment of breast cancer. Further, NDLS is being evaluated prospectively in patients with triple-negative breast cancer (ClinicalTrials.gov: NCT03671044).

Keywords: DoceAqualip, NDLS, nanosomal docetaxel lipid suspension, breast cancer

Introduction

Breast cancer is one of the most common cancers globally. In women, breast cancer is the most commonly diagnosed cancer and a leading cause of cancer mortality worldwide. As per the GLOBOCAN 2018 report, breast cancer accounts for 11.6% of all cancer cases with 2,088,849 new cases and 626,679 (6.6%) deaths reported globally. In India, breast cancer has an incidence of 27.7% (n=162,468) among all cancers in women.

Docetaxel has emerged as the agent of choice with established efficacy and tolerability in the treatment of breast cancer. Docetaxel is approved for the treatment of locally advanced or metastatic breast cancer (MBC) and for adjuvant...
treatment of operable node-positive breast cancer.5 Docetaxel has also demonstrated efficacy and tolerability in the neoadjuvant treatment of operable breast cancer.6,7

The conventional formulation of docetaxel has several toxicity issues related to its excipients, polysorbate 80 and ethanol, such as acute hypersensitivity reactions,8,9 cumulative fluid retention,10 peripheral neuropathy,11 severe anaphylactoid reactions,12 infusion-site reactions,13 and alcohol intoxication.14,15 Corticosteroids and antihistamines are used as premedication to overcome these toxicities,16–18 but these adverse effects may still occur in some patients.19 A novel lipid based, polysorbate 80 and ethanol free formulation of docetaxel, nanosomal docetaxel lipid suspension (NDLS, DoceAqualip, of Intas Pharmaceuticals Limited, India), was developed to overcome these toxicity issues.20 NDLS has shown comparable efficacy and tolerability to conventional docetaxel in the treatment of MBC in a prospective study.20 NDLS has also demonstrated efficacy and safety for the management of breast cancer in previous retrospective studies.21,22 The current report presents a multicenter, retrospective experience in real-world practice evaluating the efficacy and safety of NDLS-based chemotherapy in the treatment of breast cancer.

Methods

Study Design

In our multicenter, observational, retrospective study, medical charts of women with breast cancer, who were treated with NDLS-based chemotherapy as part of their routine clinical care at four centers across India, were analyzed. The study endpoints were overall response rate (ORR: proportion of patients achieving complete [CR] + partial response [PR]), disease control rate (DCR: CR + PR + stable disease [SD]) and overall survival (OS, defined as time from treatment to death due to any cause; for patients who were still alive at the time of data analysis or who were lost to follow-up, OS was censored at the last recorded date that the patient was known to be alive). ORR and DCR were analyzed for patients who received NDLS-based treatment in neoadjuvant and metastatic settings, and OS was evaluated for all patients. Treatment response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.23 Incidence of adverse events (AEs) documented in the treatment charts were recorded and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Criteria version 5.24 Similarly, data on death and discontinuations were captured from patients’ health records.

Ethics Statement

The study protocol was reviewed and approved by OM ethics committee, Ahmedabad, India. The study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki, and in accordance with the International Conference on Harmonization’s Good Clinical Practice guidelines, applicable regulatory requirements, and in compliance with the protocol. Patient consent to review their medical records was not required by the committee as NDLS is already approved in India and patient confidentiality was completely maintained. In this retrospective study, no patient identifiers were used and data were anonymized.

Statistical Analyses

Demographic and baseline characteristics were summarized using descriptive statistics. Categorical variables were summarized with frequency and percentage. Continuous variables were summarized with count, mean, standard deviation, median, minimum, and maximum. Response rate was evaluated as per RECIST 1.1 and presented as frequency and percentage of patients. Survival analysis was performed to measure lifetime or the length of time until the occurrence of an event (death in case of overall survival). Survival data was analyzed using a non-parametric procedure performed on PROC LIFETEST of SAS (Version 9.4) to measure the duration of time until a specified event occurs. OS was calculated and analyzed using Kaplan–Meier method and Log rank test to estimate the survival function from lifetime data after treatment. The AEs were summarized as frequencies and percentages by type of reactions.

Results

Patients Disposition and Demographics

Data of 91 women with breast cancer, who were treated with NDLS-based chemotherapy, were analyzed. The baseline characteristics of these patients are summarized in Table 1.

NDLS was used as a 1-hour infusion in 3-week cycles at a dose of 75 mg/m² (93.4%, 85/91) or 100 mg/m² (6.6%, 6/91). NDLS-based regimens were used as first-line therapy in the majority (88.5%) of the patients. Most (n=60, 98.4%) of the patients were administered premedications; dexamethasone was the most common agent.
Granulocyte-colony stimulating factor (GCSF) was used in the majority of the patients (97.8%, 90/91) as primary prophylaxis.

NDLS-Based Treatment Regimens

The most common NDLS-based treatment regimens were: neoadjuvant setting, NDLS plus carboplatin plus trastuzumab (TCH, 33.3%, 4/12) and 5-FU plus epirubicin plus cyclophosphamide followed by NDLS (FEC→T, 25%, 3/12); adjuvant setting, NDLS plus cyclophosphamide (TC, 23%, 14/61), TCH and NDLS plus doxorubicin plus cyclophosphamide (TAC) (21.3% each, 13/61), and metastatic setting: NDLS plus carboplatin (44.4%, 8/18) and TCH (33.3%, 6/18).

Efficacy

Of 30 patients who received NDLS for the treatment of breast cancer in metastatic and neoadjuvant settings, efficacy evaluation was available for 29 patients (12/12 in neoadjuvant and 17/18 in metastatic settings). Patients who received NDLS in the adjuvant setting (n=61) were considered for safety and OS analysis. In the neoadjuvant setting, both ORR and DCR were 100% (CR: 50% [6/12], PR: 50% [6/12]), respectively (Figure 1A), whereas in the metastatic setting, ORR was

Table 1 Patient Disposition and Baseline Characteristics

| Parameters                        | All patients (N=91) | Neoadjuvant Setting (N=12) | Adjuvant Setting (N=61) | Metastatic Setting (N=18) |
|-----------------------------------|--------------------|----------------------------|-------------------------|--------------------------|
| Age (years), mean ± SD, range     | 51.3 ± 11.2 (26–76) | 51.3 ± 13.3 (31–76)       | 49.1 ± 10.8 (26–74)    | 58.9 ± 7.8 (41–75)       |
| BSA, kg/m², mean ± SD             | 1.60 ± 0.2         | 1.71 ± 0.1                 | 1.59 ± 0.2              | 1.60 ± 0.2               |
| Women, n (%)                       |                    |                            |                         |                          |
| Premenopausal                     | 29 (31.9)          | 4 (33.3)                   | 24 (39.3)               | 1 (5)                    |
| Post-menopausal                   | 62 (68.1)          | 8 (66.7)                   | 37 (60.7)               | 17 (94.4)                |
| Cancer Stage, n (%)               |                    |                            |                         |                          |
| I                                 | 3 (3.3)            | 1 (8.3)                    | 2 (3.3)                 | -                        |
| II                                | 31 (34.1)          | 2 (16.7)                   | 29 (47.4)               | -                        |
| III                               | 39 (42.9)          | 9 (75.0)                   | 30 (49.3)               | -                        |
| IV                                | 18 (19.8)          | -                          | -                       | 18 (100)                 |
| Metastasis Site, n (%)             |                    |                            |                         |                          |
| Lymph node                        | 4 (4.4)            | -                          | 4 (6.6)                 | -                        |
| Bone                              | 4 (4.4)            | -                          | -                       | 4 (22.2)                 |
| Brain                             | 1 (1.1)            | -                          | -                       | 1 (5.6)                  |
| Liver                             | 1 (1.1)            | -                          | -                       | 1 (5.6)                  |
| Lung                              | 4 (4.4)            | -                          | -                       | 4 (22.2)                 |
| Hormonal Receptor Status          |                    |                            |                         |                          |
| ER+/PR+                            | 43 (47.3)          | 8 (66.7)                   | 24 (39.3)               | 11 (61.1)                |
| HER2+                              | 38 (41.8)          | 5 (41.7)                   | 24 (39.3)               | 9 (50)                   |
| TNBC                               | 25 (27.5)          | 2 (16.7)                   | 18 (29.5)               | 5 (27.8)                 |
| ECOG Score, n (%)                 |                    |                            |                         |                          |
| 0                                 | 4 (4.4)            | 2 (3.3)                    | 2 (11.1)                | -                        |
| 1                                 | 50 (54.9)          | 36 (59)                    | 8 (44.4)                | -                        |
| 2                                 | 34 (37.4)          | 21 (34.4)                  | 7 (38.9)                | -                        |
| 3                                 | 1 (1.1)            | 1 (1.6)                    | -                       | -                        |
| Comorbid Disease, n (%)           |                    |                            |                         |                          |
| Hypertension                      | 10 (11)            | 6 (9.8)                    | 2 (11.1)                | -                        |
| Diabetes                          | 19 (20.9)          | 10 (16.4)                  | 6 (33.3)                | -                        |

Notes: *Metastasis sites were not available for four patients. *Number of patients in ER+/PR+ and HER2+ may overlap. *ECOG score not available for two patients in adjuvant setting. Other comorbid diseases included hypothyroidism, arthritis, coronary artery disease, dyslipidemia, and ischemic heart disease.

Abbreviations: BSA, body surface area; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor; SD, standard deviation; TNBC, triple-negative breast cancer.
64.7% (PR: 64.7% [11/17]) and DCR was 70.6% (PR: 64.7% [11/17], SD: 5.6% [1/17]), respectively (Figure 1B).

Overall Survival
Overall, patient survival data was collected from the date of administration of the first dose of NDLS treatment till the last follow-up date (September 30, 2018) for alive patients and date of death for patients who died. Overall, 83.5% (76/91) patients were alive at a median follow-up duration of 21.6 months (range: 2.1–49.9 months). The proportion of patients who were alive was 91.7% (11/12) in the neoadjuvant setting [median follow-up: 21.1 months (range: 2.06–46.8 months)] (Figure 2A), 90.2% (55/61) in the adjuvant setting [median follow-up: 21.6 months (range: 3.5–49.8 months)] (Figure 2B) and 44.4% (10/18) in the metastatic setting [median follow-up: 22.4 months (range: 5.1–36.9 months)] (Figure 2C). The median OS was not reached for patients treated in neoadjuvant and adjuvant settings, whereas it was 30.4 months in metastatic setting.

Safety
The data on AEs were available for 54 patients. Of these, at least one AE was reported in 46 (85.2%) patients. Grade I AEs were reported in 83.3% (45/54) patients, grade II in 42.6% (23/54), grade III in 14.8% (8/54) and grade IV in 5.6% (3/54) patients. Anemia, thrombocytopenia, lymphopenia and neutropenia were the most common hematological AEs, whereas hyperglycemia and alteration in liver function tests were the most common non-hematological AEs reported (Table 2). The AEs of interest with docetaxel such as hypersensitivity reactions, fluid retention,
neuropathy and nail disorders, were not reported with the use of NDLS in this study.

**Discussion**

Docetaxel is recommended as a single agent or in combination for the treatment of breast cancer in neoadjuvant, adjuvant and metastatic settings by several guidelines.\textsuperscript{25,26} Globally several novel docetaxel formulations are being developed to overcome the toxicities related to excipients used in the conventional docetaxel formulation, among which, NDLS was approved by the Drug Controller General of India in August 2013.

NDLS was developed using the patented (worldwide [WO2008127358], Europe [2076244], Japan [5917789] and Canada [CA2666322]) “NanoAqualip” technology.\textsuperscript{27} NDLS was developed by adding docetaxel to high pressure homogenized soy phosphatidylcholine and sodium cholesteryl sulfate in sodium citrate buffer under continuous high pressure homogenization. Nanosomal lipid-based (with generally regarded as safe [GRAS] lipids by the US Food and Drug Administration) docetaxel nanoparticles (<100 nm) may infiltrate and get trapped in the damaged tumor vasculature and necrotic tumor tissue collagen material resulting in increased retention [enhanced permeability and retention (EPR) effect]. The efficacy and safety of NDLS has been demonstrated in breast, gastric, ovarian, cervical, penile, hormone refractory prostate and non-small cell lung cancers.\textsuperscript{21,28-31} Furthermore, a panel of oncology experts has recommended using NDLS in patients with metastatic disease, those at risk of hypersensitivity reactions, diabetics and those in whom steroids need to be avoided.\textsuperscript{32}

The current study presents the findings of NDLS-based chemotherapy in breast cancer patients in neoadjuvant, adjuvant and metastatic settings. In neoadjuvant settings, achieving pathologic complete response (pCR) is associated with significantly reduced disease recurrence and improved survival in breast cancer patients.\textsuperscript{33} In our study, both ORR

**Figure 2** Kaplan-Meier estimates of overall survival in breast cancer patients: (A) neoadjuvant (n=12), (B) adjuvant (n=61), and (C) metastatic (n=18) settings. The mean survival time and its standard error were underestimated because the largest observation was censored and estimation was restricted to the largest event time.
Docetaxel in combination with anthracyclines and cyclophosphamide as concurrent (the TAC regimen) or sequentially (AC→T) has been evaluated for adjuvant treatment in many studies. In our study, NDLS was most commonly used in combination as TC, TAC and TCH regimens in adjuvant setting. The US Oncology Research Trial 9735 showed an OS of 90% with adjuvant TC regimen at a median follow-up of 5.5 years in early breast cancer patients (n=506). The 7-year follow-up, in this study, showed an OS rate of 87% with a TC regimen. The TAX316 study evaluated TAC regimen in adjuvant treatment of breast cancer and showed that 87.8% patients were alive at a median follow-up of 77 months. Jones et al, showed 98.3% alive patients at a median follow-up of 36.1 months who had received an adjuvant TCH regimen. In our study, at a median follow-up of 21.6 months (range: 3.5–49.8 months), the median OS was not reached for adjuvant setting and 90.2% (55/61) patients were still alive.

Docetaxel has been established as an effective treatment option in the treatment of MBC after failure of prior chemotherapy. Conventional docetaxel has reported an ORR of 30–47% in MBC at various dose levels. The efficacy and safety of NDLS was compared with conventional docetaxel in the management of MBC by Ahmad et al. NDLS monotherapy demonstrated an ORR of 35.5% (n=49) vs 26.3% (n=23) with conventional docetaxel at 75 mg/m² in the treatment of 72 locally advanced or MBC patients. The safety was comparable between NDLS and conventional docetaxel, though patients in the NDLS group were not premedicated with corticosteroids. In our study, NDLS plus carboplatin and TCH were the most common NDLS-based regimens used in metastatic settings. In a study by Mavroudis et al, docetaxel plus carboplatin showed an ORR of 61% in MBC patients (n=36). The NCCTG 9932 trial showed an ORR of 58% with docetaxel plus carboplatin in 35 patients. The Phase III BCIRG 007 study by Valero et al demonstrated an ORR of 72% and median OS of 37.4 months for TCH regimen in HER2+ MBC patients (n=132). TCH demonstrated an ORR of 79% (n=62) in the BCIRG 101 study and 58% (n=59) in the UCLA-ORN study for the treatment of MBC. In our analysis, NDLS-based regimens demonstrated an ORR and DCR of 64.7% and 70.6%, respectively. At a median follow-up of 22.4 months (range: 5.1–36.9 months), the median OS was 30.4 months and 44.4% patients were still alive.

Overall, NDLS-based regimens were found to be well tolerated in breast cancer patients. GCSF was used in most

**Table 2 Safety Profile of NDLS-Based Chemotherapy in Breast Cancer (n=54)**

| Adverse Event                  | All Grades, n (%) | Grade III, n (%) | Grade IV, n (%) |
|-------------------------------|------------------|-----------------|----------------|
| **Hematological AEs**         |                  |                 |                |
| Anemia                        | 40 (74.1)        | 2 (3.7)         | -              |
| Thrombocytopenia              | 25 (46.3)        | 2 (3.7)         | 2 (3.7)        |
| Lymphopenia                   | 17 (31.5)        | 3 (5.6)         | -              |
| Neutropenia                   | 5 (9.3)          | 2 (3.7)         | 2 (3.7)        |
| **Non-Hematological AEs**     |                  |                 |                |
| Hyperglycemia                 | 13 (24.1)        | -               | -              |
| Alteration in liver function test | 6 (11.1)     | 2 (3.7)         | -              |
| Alopecia                      | 2 (3.7)          | -               | -              |
| Diarrhea                      | 1 (1.9)          | -               | -              |
| Hypotension                   | 1 (1.9)          | -               | -              |
| Mucositis                     | 1 (1.9)          | -               | -              |
| Rash                          | 1 (1.9)          | -               | -              |

Notes: AEs in different grades may occur in ≥1 patients; hence, the cumulative number of patients in different grades may exceed the total number of patients with individual AEs.

and DCR rates were 100% (CR: 50%, PR: 50%) with NDLS-based chemotherapy in the neoadjuvant setting. In this analysis, only one patient was evaluated using pathological response and achieved pCR, and remaining patients were evaluated based on overall response criteria by RECIST 1.1. Furthermore, median OS was not reached for neoadjuvant settings; 91.7% patients were alive at last follow-up (median follow-up: 21.1 months; range: 2.06–46.8 months). NDLS was most commonly used as a TCH (33.3%) regimen in the neoadjuvant setting, since 5/12 (41.7%) patients in this setting were human epidermal growth factor receptor 2 positive (HER2+). Previous reports on neoadjuvant treatment with taxanes, platinum agent and trastuzumab have shown ORR rates of 87.1% (n=39), 98% (n=42) and 100% (n=32) in previous studies in patients with breast cancer treated in neoadjuvant settings. In an Indian retrospective analysis by Tiwari et al, TCH regimen (n=32) demonstrated an ORR of 100%. The Phase III BCIRG 007 study by Valero et al demonstrated an ORR of 72% and median OS of 37.4 months for TCH regimen in HER2+ MBC patients (n=132). TCH demonstrated an ORR of 79% (n=62) in the BCIRG 101 study and 58% (n=59) in the UCLA-ORN study for the treatment of MBC. In our analysis, NDLS-based regimens demonstrated an ORR and DCR of 64.7% and 70.6%, respectively. At a median follow-up of 22.4 months (range: 5.1–36.9 months), the median OS was 30.4 months and 44.4% patients were still alive.

Overall, NDLS-based regimens were found to be well tolerated in breast cancer patients. GCSF was used in most
of the patients and the safety profile of NDLS in this study is consistent with previous literature.20,22,50 In the TAX313 study, fluid retention (38%), thrombocytopenia (11%), neutropenia (94%), febrile neutropenia (7%), treatment-related grade III/IV infection (3%) and anemia (94%) were the most common AEs with conventional docetaxel. In our study, severe grade IV neutropenia and thrombocytopenia were reported in 2 (3.70%) patients, which resolved with supportive therapy. The most commonly reported grade III AEs were lymphopenia (5.6%), anemia, thrombocytopenia and neutropenia (3.7% each), and grade IV AEs were neutropenia and thrombocytopenia (3.7% each). The AEs of interest with conventional docetaxel formulation such as hypersensitivity reactions, fluid retention, neuropathy and nail disorders were not observed with NDLS in our study. Hyperglycemia was the most common non-hematological AE which could be attributed to the fact that 23.1% of the patients in this study had diabetes at baseline and the majority of the patients received corticosteroids as premedication. The major limitation of this study is its retrospective nature and data availability with respect to survival and safety. The progression-free survival (PFS) could not be captured in this study since being a real-world study, the data on progression and serial scans were not available for most of the patients at most of the follow-up timepoints. This is one of the major limitations of this study.

Conclusion
The novel nanosomal docetaxel lipid suspension (NDLS)-based chemotherapy was effective and well tolerated in managing breast cancer in all settings. Furthermore, NDLS is being evaluated prospectively in patients with triple-negative breast cancer (ClinicalTrials.gov identifier: NCT03671044)

Acknowledgments
The authors thank Mr Shreekant Sharma, MPharm, ISMPP CMPP™ (Lambda Therapeutic Research Ltd., Ahmedabad, Gujarat, India) for providing writing assistance and Dr Venugopal Madhusudhana, MBBS, EPBM, ISMPP CMPP™ (Lambda Therapeutic Research Ltd., Ahmedabad, Gujarat, India) for additional editorial assistance for the development of this manuscript. The authors also thank the clinical data management and biostatistics department of Lambda Therapeutic Research Ltd. for their contribution in the preparation of the statistical analysis report in this retrospective data collation and analysis.

Author Contributions
SS, RP, GB, SKDM performed the research, were involved in the acquisition of data, critically revised the manuscript for important intellectual content, and approved the final manuscript. NJ, DB, MAK and IA designed the study, were involved in the data interpretation, critically revised the manuscript for important intellectual content, and approved the final manuscript. All authors made substantial contributions to this study and agree to be accountable for all aspects of the work.

Funding
This study was funded by an unrestricted research grant by Intas Pharmaceuticals Ltd., Ahmedabad, Gujarat, India.

Disclosure
Drs Mujtaba A Khan, Deepak Bunger and Nisarg Joshi are employees of Intas Pharmaceuticals Ltd., India, and the product being mentioned is manufactured and marketed by Intas Ltd. Dr Imran Ahmad is an employee of Jina Pharmaceuticals Inc., USA. The authors report no other conflicts of interest in this work.

References
1. Ghoncheh M, Pournamdar Z, Salehiniya H. Incidence and mortality and epidemiology of breast cancer in the world. Asian Pac J Cancer Prev. 2016;17(S3):43–46. doi:10.7314/APJCP.2016.17.S3.43
2. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
3. National Institute for Cancer Prevention and Research. Glocoboc 2018: India Factsheet. Available from: http://cancerindia.org.in/globo can-2018-india-factsheet/. Accessed April 21, 2020.
4. Crown J, O’Leary M, Ooi WS. Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. Oncologist. 2004;9(Suppl 2(S2)):24–32. doi:10.1634/theoncologist.9-suppl_2-24
5. Taxotere® Prescribing Information. sanofi-aventis U.S. LLC, NJ 08007. Revised May, 2010.
6. Amat S, Bougnoux P, Penault-Llona F, et al. Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate. Br J Cancer. 2003;88(9):1339–1345. doi:10.1038/sj.bjc.6600916
7. von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796–1804. doi:10.1200/JCO.2011.38.8595
8. Weiszhar Z, Czécz J, Révész C, et al. Complement activation by polyethoxylated pharmaceutical surfactants: cremophor-EL, Tween-80 and Tween-20. Eur J Pharm Sci. 2012;45(4):492–498. doi:10.1016/j.ejps.2011.09.016
9. Pritchett W, Kinsley K. Benefits and risks of fosaprepitant in patients receiving emetogenic regimens. Clin J Oncol Nurs. 2016;20(5):555–556. doi:10.1188/16.CJON.555-556
44. Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. *J Clin Oncol*. 1999;17(5):1413–1424. doi:10.1200/JCO.1999.17.5.1413

45. Chan S. Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy. *Oncology (Williston Park)*. 1997;11 (8 Suppl 8):19–24.

46. Mavroudis D, Alexopoulos A, Malamos N, et al. Salvage treatment of metastatic breast cancer with docetaxel and carboplatin. A multicenter Phase II trial. *Oncology*. 2003;64(3):207–212. doi:10.1159/000069306

47. Perez EA, Suman VJ, Fitch TR, et al. A phase II trial of docetaxel and carboplatin as first-line chemotherapy for metastatic breast cancer: NCCTG study N9932. *Oncology*. 2005;69(2):117–121. doi:10.1159/000087813

48. Valero V, Forbes J, Pegram MD, et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. *J Clin Oncol*. 2011;29(2):149–156. doi:10.1200/JCO.2010.28.6450

49. Riva A, Reese D, Toppmeyer D, et al. Results of Two open-label, multicenter phase ii studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. *JNCI*. 2004;96 (10):759–769. doi:10.1093/jnci/djh133

50. Ashraf QM, Sajad QR, Khan MA, et al. Efficacy and safety of a novel nanosomal docetaxel lipid suspension as an anticancer agent - a retrospective study. *J Cancer Oncol*. 2018;2(4):000132.